Toxoplasmosis and the compromised host.
A high percentage of population shows antibodies to Toxoplasma gondii yet clinical manifestations of primary infestations are rare. Congenital and secondary forms (chorioretinitis) are serious medical conditions. An outburst in a compromised host is always serious and may be fatal. Therefore, patients subjected to immunosuppressive therapy or with pathologic immune suppression should be clinically and serologically screened and, when toxoplasmosis is diagnosed, treated for the entire period of immunosuppression.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D004199:Disease Vectors; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007933:Leucomycins / Q000627:therapeutic use; D011247:Pregnancy; D011739:Pyrimethamine / Q000627:therapeutic use; D012698:Serologic Tests; D014123:Toxoplasmosis / Q000209:etiology / Q000276:immunology* / Q000635:transmission
D000906:Antibodies; D007933:Leucomycins; D011739:Pyrimethamine